{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:40:31Z","timestamp":1753890031025,"version":"3.41.2"},"reference-count":61,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Amyloidosis is a systemic disease caused by low molecular weight protein accumulation in the extracellular space, which can lead to different degrees of damage, depending of the organ or tissue involved. The condition is defined cardiac amyloidosis (CA) when heart is affected, and it is associated with an unfavorable outcome. Different types of CA have been recognized, the most common (98%) are those associated with deposition of light chain (AL-CA), and the form secondary to transthyretin deposit. The latter can be classified into two types, a wild type (transthyretin amyloidosis wild type (ATTRwt)-CA), which mainly affects older adults, and the hereditary or variant type (ATTRh-CA or ATTRv-CA), which instead affects more often young people and is associated with genetic alterations. The atrial involvement can be isolated or linked to CA with a nonspecific clinical presentation represented by new onset atrial fibrillation (AF), diastolic dysfunction and heart failure with preserved ejection fraction, or thromboembolism and stroke. Untreated patients have a median survival rate of 9 years for AL-CA and 7 years for ATTR-CA. By contrast, AL-CA and ATTR-CA treated patients have a median survival rate of 24 and 10 years, respectively. Atrial involvement in CA is a common but poor studied event, and alterations of performance can anticipate the anatomical damage. Recently, numerous advances have been made in the diagnostic field with improvements in the available techniques. An early diagnosis therefore allows a more effective therapeutic strategy with a positive impact on prognosis and mortality rate. A multimodality approach to the diagnosis of atrial involvement from CA is therefore recommended, and standard echocardiography, advanced Doppler-echocardiography (DE) and cardiac magnetic resonance (CMR) can be useful to detect early signs of CA and to estabilish an appropriate treatment.<\/jats:p>","DOI":"10.31083\/j.rcm2502073","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T08:19:52Z","timestamp":1708676392000},"source":"Crossref","is-referenced-by-count":3,"title":["Current Perspectives on Atrial Amyloidosis: A Narrative Review"],"prefix":"10.31083","volume":"25","author":[{"given":"Marco","family":"Tana","sequence":"first","affiliation":[{"name":"Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, St Annunziata Hospital, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, G. D\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Tana","sequence":"first","affiliation":[{"name":"Geriatrics Clinic, St Annunziata Hospital, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Domenica","family":"Guglielmi","sequence":"first","affiliation":[{"name":"Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, St Annunziata Hospital, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Stefanelli","sequence":"first","affiliation":[{"name":"Department of Innovative Technologies in Medicine and Dentistry, G. D\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Mantini","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, G. D\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Porreca","sequence":"first","affiliation":[{"name":"Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, St Annunziata Hospital, 66100 Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, G. D\u2019Annunzio University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tana M, Tana C, Palmiero G, Mantini C, Coppola MG, Limongelli G, et al. Imaging findings of right cardiac amyloidosis: impact on prognosis and clinical course. Journal of Ultrasound. 2023; 26: 605\u2013614.","DOI":"10.1007\/s40477-023-00789-1"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; 42: 1554\u20131568.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gertz MA. Cardiac Amyloidosis. Heart Failure Clinics. 2022; 18: 479\u2013488.","DOI":"10.1016\/j.hfc.2022.02.005"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Advances. 2018; 2: 1046\u20131053.","DOI":"10.1182\/bloodadvances.2018016402"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bandera F, Martone R, Chacko L, Ganesananthan S, Gilbertson JA, Ponticos M, et al. Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis. JACC. Cardiovascular Imaging. 2022; 15: 17\u201329.","DOI":"10.1016\/j.jcmg.2021.06.022"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Brons M, Muller SA, Rutten FH, van der Meer MG, Vrancken AFJE, Minnema MC, et al. Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. European Heart Journal Open. 2022; 2: oeac011.","DOI":"10.1093\/ehjopen\/oeac011"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Tini G, Milani P, Zampieri M, Caponetti AG, Fabris F, Foli A, et al. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study. European Journal of Heart Failure. 2023; 25: 845\u2013853.","DOI":"10.1002\/ejhf.2823"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Briasoulis A, Bampatsias D, Papamichail A, Kuno T, Skoularigis J, Xanthopoulos A, et al. Invasive and Non-Invasive Diagnostic Pathways in the Diagnosis of Cardiac Amyloidosis. Journal of Cardiovascular Development and Disease. 2023; 10: 256.","DOI":"10.3390\/jcdd10060256"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012; 126: 1286\u20131300.","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Vergaro G, Aimo A, Rapezzi C, Castiglione V, Fabiani I, Pucci A, et al. Atrial amyloidosis: mechanisms and clinical manifestations. European Journal of Heart Failure. 2022; 24: 2019\u20132028.","DOI":"10.1002\/ejhf.2650"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in Cardiac Amyloidosis. JACC. Clinical Electrophysiology. 2020; 6: 351\u2013361.","DOI":"10.1016\/j.jacep.2020.01.004"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation. Heart Failure. 2019; 12: e006075.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Cappelli F, Tini G, Russo D, Emdin M, Del Franco A, Vergaro G, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid. 2021; 28: 12\u201318.","DOI":"10.1080\/13506129.2020.1798922"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Versteylen MO, Brons M, Teske AJ, Oerlemans MIFJ. Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients. Biomedicines. 2022; 10: 1768.","DOI":"10.3390\/biomedicines10081768"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Monte IP, Faro DC, Trimarchi G, de Gaetano F, Campisi M, Losi V, et al. Left Atrial Strain Imaging by Speckle Tracking Echocardiography: The Supportive Diagnostic Value in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. Journal of Cardiovascular Development and Disease. 2023; 10: 261.","DOI":"10.3390\/jcdd10060261"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis [Erratum in: Circulation. 2008; 118: e131. Syed, Imran I [corrected to Syed, Imran S]]. Circulation. 2007; 116: 2420\u20132426.","DOI":"10.1161\/CIRCULATIONAHA.107.697763"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, et al. High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology. 2019; 73: 1733\u20131734.","DOI":"10.1016\/j.jacc.2019.01.035"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020; 142: e7\u2013e22.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society\/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. The Canadian Journal of Cardiology. 2020; 36: 322\u2013334.","DOI":"10.1016\/j.cjca.2019.12.034"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sanchis K, Cariou E, Colombat M, Ribes D, Huart A, Cintas P, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid: the International Journal of Experimental and Clinical Investigation. 2019; 26: 128\u2013138.","DOI":"10.1080\/13506129.2019.1620724"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Papathanasiou M, Jakstaite AM, Oubari S, Siebermair J, Wakili R, Hoffmann J, et al. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis. ESC Heart Failure. 2022; 9: 1740\u20131748.","DOI":"10.1002\/ehf2.13851"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W, et al. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. JACC. Clinical Electrophysiology. 2020; 6: 1118\u20131127.","DOI":"10.1016\/j.jacep.2020.04.019"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Anderson KP. Cardiac Amyloidosis and the Risks of Cardioversion. Journal of the American College of Cardiology. 2019; 73: 598\u2013601.","DOI":"10.1016\/j.jacc.2018.10.080"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2019; 73: 589\u2013597.","DOI":"10.1016\/j.jacc.2018.10.079"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Csecs I, Merkely B, Wilson BD. Cardiac Amyloidosis and Electrical Cardioversion: Is the Thrombus There or Not? Journal of the American College of Cardiology. 2019; 73: 2909\u20132910.","DOI":"10.1016\/j.jacc.2019.03.491"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Dale Z, Chandrashekar P, Al-Rashdan L, Kim M, Masri A, Nazer B. Management Strategies for Atrial Fibrillation and Flutter in Patients with Transthyretin Cardiac Amyloidosis. The American Journal of Cardiology. 2021; 157: 107\u2013114.","DOI":"10.1016\/j.amjcard.2021.07.028"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Briasoulis A, Kourek C, Papamichail A, Loritis K, Bampatsias D, Repasos E, et al. Arrhythmias in Patients with Cardiac Amyloidosis: A Comprehensive Review on Clinical Management and Devices. Journal of Cardiovascular Development and Disease. 2023; 10: 337.","DOI":"10.3390\/jcdd10080337"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"R\u00f6cken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002; 106: 2091\u20132097.","DOI":"10.1161\/01.CIR.0000034511.06350.DF"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Yang Z, Subati T, Kim K, Murphy MB, Dougherty OP, Christopher IL, et al. Natriuretic Peptide Oligomers Cause Proarrhythmic Metabolic and Electrophysiological Effects in Atrial Myocytes. Circulation. Arrhythmia and Electrophysiology. 2022; 15: e010636.","DOI":"10.1161\/CIRCEP.121.010636"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. Journal of the American College of Cardiology. 2004; 43: 410\u2013415.","DOI":"10.1016\/j.jacc.2003.08.043"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981; 63: 188\u2013196.","DOI":"10.1161\/01.CIR.63.1.188"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Oghina S, Bougouin W, B\u00e9zard M, Kharoubi M, Komajda M, Cohen-Solal A, et al. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC. Heart Failure. 2021; 9: 169\u2013178.","DOI":"10.1016\/j.jchf.2020.12.005"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Oghina S, Delbarre MA, Poullot E, Belhadj K, Fanen P, Damy T. Cardiac amyloidosis: State of art in 2022. La Revue De Medecine Interne. 2022; 43: 537\u2013544.","DOI":"10.1016\/j.revmed.2022.04.036"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Perry R, Selvanayagam JB. Echocardiography in Infiltrative Cardiomyopathy. Heart, Lung & Circulation. 2019; 28: 1365\u20131375.","DOI":"10.1016\/j.hlc.2019.04.017"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology. 2016; 68: 1323\u20131341.","DOI":"10.1016\/j.jacc.2016.06.053"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. Journal of the American College of Cardiology. 2007; 50: 2101\u20132110.","DOI":"10.1016\/j.jacc.2007.08.028"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: updates in diagnosis and management. Archives of Cardiovascular Diseases. 2013; 106: 528\u2013540.","DOI":"10.1016\/j.acvd.2013.06.051"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Martel H, Rique A, Piazzai C, Mancini J, Dumonceau RG, Arregle F, et al. Ejection Fraction Basal Strain Ratio: A New Composite Echocardiographic Deformation Parameter Allowing Differentiation of Cardiac Amyloidosis From Hypertrophic Cardiomyopathies. Journal of the American Society of Echocardiography. 2023; 36: 555\u2013557.","DOI":"10.1016\/j.echo.2022.12.021"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Abdalla I, Murray RD, Lee JC, Stewart WJ, Tajik AJ, Klein AL. Duration of pulmonary venous atrial reversal flow velocity and mitral inflow a wave: new measure of severity of cardiac amyloidosis. Journal of the American Society of Echocardiography. 1998; 11: 1125\u20131133.","DOI":"10.1016\/S0894-7317(98)80007-2"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Ballantyne B, Manian U, Sheyin O, Davey R, De S. Stroke risk and atrial mechanical dysfunction in cardiac amyloidosis. ESC Heart Failure. 2020; 7: 705\u2013707.","DOI":"10.1002\/ehf2.12602"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Mohty D, Petitalot V, Magne J, Fadel BM, Boulogne C, Rouabhia D, et al. Author\u2019s reply. Journal of Cardiology. 2018; 72: 368.","DOI":"10.1016\/j.jjcc.2018.02.004"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. Journal of the American College of Cardiology. 2021; 77: 128\u2013139.","DOI":"10.1016\/j.jacc.2020.11.006"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Ricci F, Ceriello L, Khanji MY, Dangas G, Bucciarelli-Ducci C, Di Mauro M, et al. Prognostic Significance of Cardiac Amyloidosis in Patients With Aortic Stenosis: A Systematic Review and Meta-Analysis. JACC. Cardiovascular Imaging. 2021; 14: 293\u2013295.","DOI":"10.1016\/j.jcmg.2020.07.011"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, et al. Left atrial structure and function in cardiac amyloidosis. European Heart Journal. Cardiovascular Imaging. 2017; 18: 1128\u20131137.","DOI":"10.1093\/ehjci\/jex097"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Brand A, Frumkin D, H\u00fcbscher A, Dreger H, Stangl K, Baldenhofer G, et al. Phasic left atrial strain analysis to discriminate cardiac amyloidosis in patients with unclear thick heart pathology. European Heart Journal. Cardiovascular Imaging. 2021; 22: 680\u2013687.","DOI":"10.1093\/ehjci\/jeaa043"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Rausch K, Scalia GM, Sato K, Edwards N, Lam AKY, Platts DG, et al. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. The International Journal of Cardiovascular Imaging. 2021; 37: 81\u201390.","DOI":"10.1007\/s10554-020-01948-9"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003; 107: 2446\u20132452.","DOI":"10.1161\/01.CIR.0000068313.67758.4F"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC. Cardiovascular Imaging. 2010; 3: 333\u2013342.","DOI":"10.1016\/j.jcmg.2009.11.013"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Palka P, Lange A, Donnelly JE, Scalia G, Burstow DJ, Nihoyannopoulos P. Doppler tissue echocardiographic features of cardiac amyloidosis. Journal of the American Society of Echocardiography. 2002; 15: 1353\u20131360.","DOI":"10.1067\/mje.2002.125285"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Lyne JC, Petryka J, Pennell DJ. Atrial enhancement by cardiovascular magnetic resonance in cardiac amyloidosis. European Heart Journal. 2008; 29: 212.","DOI":"10.1093\/eurheartj\/ehm351"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Tana M, Tana C, Panarese A, Mantini C, Ricci F, Porreca E. Clinical and Cardiovascular Magnetic Resonance Imaging Features of Cardiac Amyloidosis. Reviews in Cardiovascular Medicine. 2023; 24: 291.","DOI":"10.31083\/j.rcm2410291"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Di Bella G, Minutoli F, Madaffari A, Mazzeo A, Russo M, Donato R, et al. Left atrial function in cardiac amyloidosis. Journal of Cardiovascular Medicine. 2016; 17: 113\u2013121.","DOI":"10.2459\/JCM.0000000000000188"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Kwong RY, Heydari B, Abbasi S, Steel K, Al-Mallah M, Wu H, et al. Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. The American Journal of Cardiology. 2015; 116: 622\u2013629.","DOI":"10.1016\/j.amjcard.2015.05.021"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"de Gregorio C, Dattilo G, Casale M, Terrizzi A, Donato R, Di Bella G. Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy - Comparative Strain Imaging Study. Circulation Journal. 2016; 80: 1830\u20131837.","DOI":"10.1253\/circj.CJ-16-0364"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Chang P, Xiao J, Hu Z, Kwan AC, Fan Z. Imaging of left heart intracardiac thrombus: clinical needs, current imaging, and emerging cardiac magnetic resonance techniques. Therapeutic Advances in Cardiovascular Disease. 2022; 16: 17539447221107737.","DOI":"10.1177\/17539447221107737"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Sciacca V, Eckstein J, K\u00f6rperich H, Fink T, Bergau L, El Hamriti M, et al. Magnetic-Resonance-Imaging-Based Left Atrial Strain and Left Atrial Strain Rate as Diagnostic Parameters in Cardiac Amyloidosis. Journal of Clinical Medicine. 2022; 11: 3150.","DOI":"10.3390\/jcm11113150"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhao R, Deng W, Li Y, An S, Qian Y, et al. Left Atrial and Ventricular Strain Differentiates Cardiac Amyloidosis and Hypertensive Heart Disease: A Cardiac MR Feature Tracking Study. Academic Radiology. 2023; 30: 2521\u20132532.","DOI":"10.1016\/j.acra.2023.02.003"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Palmer C, Truong VT, Slivnick JA, Wolking S, Coleman P, Mazur W, et al. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study. Scientific Reports. 2022; 12: 140.","DOI":"10.1038\/s41598-021-03359-9"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lu J, Yang Z, Tang D, Luo Y, Xiang C, Zhou X, et al. The correlation of left atrial dysfunction and amyloid load in patients with immunoglobulin light-chain cardiac amyloidosis: a 3T cardiac magnetic resonance study. The British Journal of Radiology. 2023; 96: 20220985.","DOI":"10.1259\/bjr.20220985"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Eckstein J, K\u00f6rperich H, Weise Vald\u00e9s E, Sciacca V, Paluszkiewicz L, Burchert W, et al. CMR-based right ventricular strain analysis in cardiac amyloidosis and its potential as a supportive diagnostic feature. International Journal of Cardiology. Heart & Vasculature. 2022; 44: 101167.","DOI":"10.1016\/j.ijcha.2022.101167"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Benjamin MM, Arora P, Munir MS, Darki A, Liebo M, Yu M, et al. Association of Left Atrial Hemodynamics by Magnetic Resonance Imaging With Long-Term Outcomes in Patients With Cardiac Amyloidosis. Journal of Magnetic Resonance Imaging. 2023; 57: 1275\u20131284.","DOI":"10.1002\/jmri.28320"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/2\/10.31083\/j.rcm2502073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T19:28:52Z","timestamp":1732735732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/2\/10.31083\/j.rcm2502073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S1530-6550(24)01290-0"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2502073","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"73"}}